NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $7.47 -0.22 (-2.86%) Closing price 04:00 PM EasternExtended Trading$7.53 +0.06 (+0.75%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Astria Therapeutics Stock (NASDAQ:ATXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Astria Therapeutics alerts:Sign Up Key Stats Today's Range$7.36▼$7.7850-Day Range$6.18▼$7.8452-Week Range$3.56▼$12.52Volume365,841 shsAverage Volume437,662 shsMarket Capitalization$421.61 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company Overview Astria Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues. Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles. Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.AI Generated. May Contain Errors. Read More Astria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreATXS MarketRank™: Astria Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 529th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAstria Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAstria Therapeutics has a consensus price target of $29.50, representing about 294.9% upside from its current price of $7.47.Amount of Analyst CoverageAstria Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Astria Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.49% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.49% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.41 News SentimentAstria Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Astria Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for ATXS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows4 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXS Stock News HeadlinesAstria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEAOctober 3, 2025 | businesswire.comAstria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT TrialOctober 2, 2025 | finance.yahoo.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 7 at 2:00 AM | Porter & Company (Ad)Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | businesswire.comAstria Therapeutics price target raised to $26 from $25 at Evercore ISIOctober 1, 2025 | msn.comAstria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and VenereologySeptember 17, 2025 | theglobeandmail.comAstria Therapeutics announces initial results from STAR-0310 trialSeptember 17, 2025 | msn.comAstria Therapeutics price target raised to $20 from $16 at H.C. WainwrightSeptember 17, 2025 | msn.comSee More Headlines ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $8.94 at the beginning of the year. Since then, ATXS stock has decreased by 16.4% and is now trading at $7.47. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its quarterly earnings data on Tuesday, August, 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. When did Astria Therapeutics' stock split? Astria Therapeutics shares reverse split on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Astria Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY). Company Calendar Last Earnings8/12/2025Today10/07/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Price Target for Astria Therapeutics$29.50 High Price Target$49.00 Low Price Target$20.00 Potential Upside/Downside+294.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.39% Return on Assets-36.08% Debt Debt-to-Equity RatioN/A Current Ratio14.89 Quick Ratio14.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book1.88Miscellaneous Outstanding Shares56,435,000Free Float53,895,000Market Cap$421.57 million OptionableOptionable Beta0.43 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ATXS) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.